anti-APRIL (mouse), mAb (rec.) (blocking) (Apry-1-1) (Fc LAEA-PG)
AG-27B-0023-C100 100 µg
Data Sheet: 
SDS:
SDS:
Reactivity
Mouse
Applications
ELISA, FUNC (Blocking), IP
Source / Host
Produced without the use of animals. Purified from HEK 293 cell culture supernatant.
Specificity
Recognizes mouse APRIL. Does not recognize human APRIL and mouse/human BAFF.
Clone
Apry-1-1
Shipment
BLUE ICE
Short Term Storage
+4°C
Long Term Storage
-20°C
Shelf Life
Stable for at least 1 month after receipt when stored at +4°C. Stable for at least 1 year after receipt when stored at -20°C.
Description
Recombinant Antibody. Recognizes mouse APRIL. Does not recognize human APRIL and mouse/human BAFF. Source: HEK293. Isotype: Mouse IgG2blambda. Immunogen: Mouse APRIL (aa 98-232). Applications: ELISA, FUNC (Blocking), IP. Inhibits the binding of mouse APRIL to BCMA and TACI. Works in vitro and in vivo. APRIL is a cytokine that belongs to the TNF superfamily and binds to TACI and BCMA. It is implicated in the regulation of tumor cell growth and is involved in monocyte/macrophage-mediated immunological processes. anti-APRIL (mouse), mAb (rec.) (Blocking) (Apry-1-1) (Fc LAEA-PG) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc mouse portion with mutations LAEA-PG and then produced in mammalian cells to generate an IgG like scFv-Fc (LAEA-PG) fusion protein. Mutations LAEA-PG inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected.
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
